Dismissal Of AstraZeneca Securities Action Upheld
A federal appellate court has affirmed a lower court decision dismissing a proposed class action accusing AstraZeneca PLC of misleading its investors about the safety and effectiveness of Exanta, a blood...To view the full article, register now.
Already a subscriber? Click here to view full article